Actively Recruiting
Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Led by Anhui Provincial Hospital · Updated on 2024-06-17
30
Participants Needed
1
Research Sites
90 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy in the diagnosis, recurrence and metastasis of prostate cancer, and to compare with \[18F\]F-PSMA-1007.
CONDITIONS
Official Title
Head-to-head Comparison of [18F]F-PSMA-N5 With [18F]F-PSMA-1007 PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged from 18 to 90 years old
- Complete MRI images and clinical data such as PSA level and Gleason grade
- Prostate cancer detected by PSA or imaging, or clinically suspected recurrence after treatment
- Undergo both [18F]F-PSMA-N5 and [18F]F-PSMA-1007 PET/CT exams within two weeks
- Willing to have surgery or needle biopsy for pathological confirmation
- Signed informed consent
You will not qualify if you...
- Unable to cooperate with the examination
- Having other malignant tumors
- History of alcohol allergy
- Liver or kidney dysfunction
- Any other condition making participation inappropriate according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of China University of Science and Technology（Anhui Provincial Hospital）
Hefei, Anhui, China, 230000
Actively Recruiting
Research Team
Q
Qiang Xie, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here